

NEUROLOGIX INC/DE  
Form 8-K  
May 14, 2010

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): May 11, 2010**

**Neurologix, Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**

(State or other Jurisdiction of  
Incorporation)

**000-13347**

(Commission File Number)

**06-1582875**

(IRS Employer Identification No.)

**One Bridge Plaza, Fort Lee, New Jersey**

(Address of Principal Executive Offices)

**07024**

(Zip Code)

Registrant's telephone number, including area code: **(201) 592-6451**

(Former name or former address if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.07. Submission of Matters to a Vote of Security Holders**

Neurologix, Inc. (the Company) held its Annual Meeting of Stockholders (the Annual Meeting) on May 11, 2010. At the Annual Meeting, the Company's stockholders (i) elected Mr. Reginald L. Hardy and Dr. Jeffrey B. Reich to serve as Class I directors for a term expiring at the Annual Meeting in 2013, (ii) elected Mr. Clark A. Johnson to serve as a Class III director for a term expiring at the Annual Meeting in 2012 and (iii) approved the amendments to the Company's 2000 Stock Option Plan (the Plan) that (a) increased the number of shares of the Company's common stock available for issuance pursuant to the Plan from 6,000,000 to 8,000,000, (b) extended the expiration date of the Plan for five years and (c) amended the name of the Plan from the Arinco Computer Systems Inc. 2000 Stock Option Plan to the Neurologix, Inc. 2000 Stock Option Plan. The votes on these matters are as follows:

1. The election of Mr. Reginald L. Hardy and Dr. Jeffrey B. Reich to serve as Class II directors for a term expiring at the Annual Meeting in 2013

<b>Director</b>	<b>For</b>	<b>Withhold Authority</b>	<b>Broker Non-Votes</b>
Reginald L. Hardy	45,524,983.5402	89,402	8,960,577
Jeffrey B. Reich	45,532,233.5402	82,152	8,960,577

2. The election of Mr. Clark A. Johnson to serve as a Class III director for a term expiring at the Annual Meeting in 2012

<b>Director</b>	<b>For</b>	<b>Withhold Authority</b>	<b>Broker Non-Votes</b>
Clark A. Johnson	45,520,212.5402	94,173	8,960,577

3. The approval of amendments to the Company's 2000 Stock Option Plan as described above

<b>For</b>	<b>Against</b>	<b>Abstain</b>	<b>Broker Non-Votes</b>
45,419,287.5402	179,577	15,521	8,960,577

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Neurologix, Inc.

By: /s/ Marc L. Panoff

Name: Marc L. Panoff

Title: Chief Financial Officer, Secretary,  
Treasurer

Date: May 14, 2010